Show simple item record

dc.contributor.authorPhillips, K-Aen_US
dc.contributor.authorLiao, Yen_US
dc.contributor.authorMilne, RLen_US
dc.contributor.authorMacInnis, RJen_US
dc.contributor.authorCollins, IMen_US
dc.contributor.authorBuchsbaum, Ren_US
dc.contributor.authorWeideman, PCen_US
dc.contributor.authorBickerstaffe, Aen_US
dc.contributor.authorNesci, Sen_US
dc.contributor.authorChung, WKen_US
dc.contributor.authorSouthey, MCen_US
dc.contributor.authorKnight, JAen_US
dc.contributor.authorWhittemore, ASen_US
dc.contributor.authorDite, GSen_US
dc.contributor.authorGoldgar, Den_US
dc.contributor.authorGiles, GGen_US
dc.contributor.authorGlendon, Gen_US
dc.contributor.authorCuzick, Jen_US
dc.contributor.authorAntoniou, ACen_US
dc.contributor.authorAndrulis, ILen_US
dc.contributor.authorJohn, EMen_US
dc.contributor.authorDaly, MBen_US
dc.contributor.authorBuys, SSen_US
dc.contributor.authorHopper, JLen_US
dc.contributor.authorTerry, MBen_US
dc.contributor.authorkConFab Investigatorsen_US
dc.date.accessioned2020-02-04T09:20:47Z
dc.date.available2019-08-20en_US
dc.date.issued2019-12en_US
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/62618
dc.description.abstractBackground: iPrevent is an online breast cancer (BC) risk management decision support tool. It uses an internal switching algorithm, based on a woman's risk factor data, to estimate her absolute BC risk using either the International Breast Cancer Intervention Study (IBIS) version 7.02, or Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm version 3 models, and then provides tailored risk management information. This study assessed the accuracy of the 10-year risk estimates using prospective data. Methods: iPrevent-assigned 10-year invasive BC risk was calculated for 15 732 women aged 20-70 years and without BC at recruitment to the Prospective Family Study Cohort. Calibration, the ratio of the expected (E) number of BCs to the observed (O) number and discriminatory accuracy were assessed. Results: During the 10 years of follow-up, 619 women (3.9%) developed BC compared with 702 expected (E/O = 1.13; 95% confidence interval [CI] =1.05 to 1.23). For women younger than 50 years, 50 years and older, and BRCA1/2-mutation carriers and noncarriers, E/O was 1.04 (95% CI = 0.93 to 1.16), 1.24 (95% CI = 1.11 to 1.39), 1.13 (95% CI = 0.96 to 1.34), and 1.13 (95% CI = 1.04 to 1.24), respectively. The C-statistic was 0.70 (95% CI = 0.68 to 0.73) overall and 0.74 (95% CI = 0.71 to 0.77), 0.63 (95% CI = 0.59 to 0.66), 0.59 (95% CI = 0.53 to 0.64), and 0.65 (95% CI = 0.63 to 0.68), respectively, for the subgroups above. Applying the newer IBIS version 8.0b in the iPrevent switching algorithm improved calibration overall (E/O = 1.06, 95% CI = 0.98 to 1.15) and in all subgroups, without changing discriminatory accuracy. Conclusions: For 10-year BC risk, iPrevent had good discriminatory accuracy overall and was well calibrated for women aged younger than 50 years. Calibration may be improved in the future by incorporating IBIS version 8.0b.en_US
dc.format.extentpkz066 - ?en_US
dc.languageengen_US
dc.language.isoenen_US
dc.relation.ispartofJNCI Cancer Spectren_US
dc.rightsCreative Commons Attribution-NonCommercial-NoDerivs licence
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.titleAccuracy of Risk Estimates from the iPrevent Breast Cancer Risk Assessment and Management Tool.en_US
dc.typeArticle
dc.rights.holder© The Author(s) 2019.
dc.identifier.doi10.1093/jncics/pkz066en_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/31853515en_US
pubs.issue4en_US
pubs.notesNot knownen_US
pubs.publication-statusPublished onlineen_US
pubs.volume3en_US
dcterms.dateAccepted2019-08-20en_US
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US
qmul.funderCancer Prevention programme grant::Cancer Research UKen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Creative Commons Attribution-NonCommercial-NoDerivs licence
Except where otherwise noted, this item's license is described as Creative Commons Attribution-NonCommercial-NoDerivs licence